CL2011003003A1 - Composicion tensioactiva reconstituida que comprende un polipeptido análogo a la proteína surfactante c nativa, un polipeptido análogo a la proteína surfactante b nativa, un fosfolipido monoinsaturado y un fosfolipido saturado, útil para el tratamiento del síndrome de dificultad respiratoria. - Google Patents

Composicion tensioactiva reconstituida que comprende un polipeptido análogo a la proteína surfactante c nativa, un polipeptido análogo a la proteína surfactante b nativa, un fosfolipido monoinsaturado y un fosfolipido saturado, útil para el tratamiento del síndrome de dificultad respiratoria.

Info

Publication number
CL2011003003A1
CL2011003003A1 CL2011003003A CL2011003003A CL2011003003A1 CL 2011003003 A1 CL2011003003 A1 CL 2011003003A1 CL 2011003003 A CL2011003003 A CL 2011003003A CL 2011003003 A CL2011003003 A CL 2011003003A CL 2011003003 A1 CL2011003003 A1 CL 2011003003A1
Authority
CL
Chile
Prior art keywords
phospholipid
analog polypeptide
native
surfactant protein
useful
Prior art date
Application number
CL2011003003A
Other languages
English (en)
Inventor
Fausto Pivetti
Monica Bocchi
Raschini Annamaria Soliani
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41055357&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011003003(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of CL2011003003A1 publication Critical patent/CL2011003003A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/395—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0082—Lung surfactant, artificial mucus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Cosmetics (AREA)
  • General Preparation And Processing Of Foods (AREA)

Abstract

Composición tensioactiva reconstituida que comprende un polipéptido análogo a la proteína tensioactiva sp-c nativa; agente tensioactivo; formulación farmacéutica; kit.
CL2011003003A 2009-06-05 2011-11-25 Composicion tensioactiva reconstituida que comprende un polipeptido análogo a la proteína surfactante c nativa, un polipeptido análogo a la proteína surfactante b nativa, un fosfolipido monoinsaturado y un fosfolipido saturado, útil para el tratamiento del síndrome de dificultad respiratoria. CL2011003003A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09162052 2009-06-05

Publications (1)

Publication Number Publication Date
CL2011003003A1 true CL2011003003A1 (es) 2012-05-18

Family

ID=41055357

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011003003A CL2011003003A1 (es) 2009-06-05 2011-11-25 Composicion tensioactiva reconstituida que comprende un polipeptido análogo a la proteína surfactante c nativa, un polipeptido análogo a la proteína surfactante b nativa, un fosfolipido monoinsaturado y un fosfolipido saturado, útil para el tratamiento del síndrome de dificultad respiratoria.

Country Status (35)

Country Link
US (1) US8399406B2 (es)
EP (1) EP2438086B1 (es)
JP (1) JP5666569B2 (es)
KR (1) KR101668137B1 (es)
CN (1) CN102459327B (es)
AR (1) AR076973A1 (es)
AU (1) AU2010256066B2 (es)
BR (1) BRPI1010120B1 (es)
CA (1) CA2764454C (es)
CL (1) CL2011003003A1 (es)
CO (1) CO6470858A2 (es)
CY (1) CY1118676T1 (es)
DK (1) DK2438086T3 (es)
EA (1) EA021163B1 (es)
ES (1) ES2621974T3 (es)
GE (1) GEP20135967B (es)
HR (1) HRP20170445T1 (es)
HU (1) HUE034053T2 (es)
IL (1) IL216718A (es)
JO (1) JO3226B1 (es)
LT (1) LT2438086T (es)
MA (1) MA33374B1 (es)
ME (1) ME01279B (es)
MX (1) MX2011012951A (es)
MY (1) MY159464A (es)
NZ (1) NZ596848A (es)
PE (1) PE20120541A1 (es)
PL (1) PL2438086T3 (es)
PT (1) PT2438086T (es)
SG (1) SG176305A1 (es)
SI (1) SI2438086T1 (es)
TN (1) TN2011000558A1 (es)
TW (1) TWI457132B (es)
UA (1) UA103526C2 (es)
WO (1) WO2010139442A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5658031B2 (ja) 2007-06-22 2015-01-21 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 薄膜凍結による安定したサブミクロンのペプチド又はタンパク質粒子の形成
JP2014514275A (ja) * 2011-03-10 2014-06-19 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム タンパク質ナノ粒子分散系
EP2812018B1 (en) * 2012-02-09 2018-12-05 University Of Rochester Novel sp-b&sp-c peptides, synthetic lung surfactants, and use thereof
WO2014079898A1 (en) 2012-11-21 2014-05-30 Chiesi Farmaceutici S.P.A. Reconstituted pulmonary surfactants
CN104382942A (zh) * 2014-11-05 2015-03-04 烟台东诚药业集团股份有限公司 一种猪肺表面活性物质混悬液制备新工艺
EP3285645B1 (en) 2015-04-22 2020-08-12 Chiesi Farmaceutici S.p.A. System for effective breath-synchronized delivery of medicament to the lungs
EP3106090A1 (en) 2015-06-15 2016-12-21 CHIESI FARMACEUTICI S.p.A. System for effective breath-synchronized delivery of medicament to the lungs
WO2016173634A1 (en) 2015-04-28 2016-11-03 Chiesi Farmaceutici S.P.A Device for facilitating the administration of a medicament to the lung by a catheter
EP3452041A4 (en) * 2016-03-07 2020-11-11 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Compositions and methods for administering ppar agonists, surfactant peptides and phospholipids
WO2018019719A1 (en) 2016-07-28 2018-02-01 Chiesi Farmaceutici S.P.A Method and system for delivery of an aerosolized medicament
MX2019001854A (es) * 2016-08-24 2019-11-11 Chiesi Farm Spa Formulacion farmaceutica estable que comprende una composicion de tensioactivo pulmonar reconstituido.
WO2018077623A1 (en) 2016-10-26 2018-05-03 Chiesi Farmaceutici S.P.A. Device for facilitating the administration of a medicament to the lung by a catheter
AU2017384467B2 (en) 2016-12-22 2023-10-19 Chiesi Farmaceutici S.P.A. A therapeutic combination comprising a pulmonary surfactant and a steroid for the treatment of evolving BPD
TW201927286A (zh) 2017-12-15 2019-07-16 義大利商凱西製藥公司 用於噴霧投藥之包含肺表面張力素的藥學調配物
WO2019115771A1 (en) 2017-12-15 2019-06-20 Pari Pharma Gmbh Nebuliser system, holding system, combination comprising nebuliser system and holding system, and aerosol administration method
MA52353A (fr) 2018-04-23 2021-04-28 Chiesi Farm Spa Combinaison thérapeutique comprenant un tensioactif pulmonaire et un stéroïde pour la prophylaxie de la dbp
EP3666315A1 (en) 2018-12-14 2020-06-17 PARI Pharma GmbH Aerosol delivery device and method of operating the aerosol delivery device
EP3666316A1 (en) 2018-12-14 2020-06-17 PARI Pharma GmbH Aerosol delivery device and method of operating the aerosol delivery device
EP3843105A1 (en) 2019-12-23 2021-06-30 PARI Pharma GmbH Control device for aerosol nebulizer system
US20230257446A1 (en) 2020-01-28 2023-08-17 Chiesi Farmaceutici S.P.A. Polypeptides having improved properties
JP2024524512A (ja) 2021-07-05 2024-07-05 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ 肺サーファクタントを調製する方法
EP4411745A1 (en) 2023-02-01 2024-08-07 Pari Medical Holding GmbH Medical evaluation method, aerosol nebulizer and medical evaluation system
EP4464236A1 (en) 2023-05-15 2024-11-20 Pari Medical Holding GmbH Method of operating an inhalation device, inhalation device and inhalation device system for providing inhalation process feedback
EP4464354A1 (en) 2023-05-15 2024-11-20 Pari Medical Holding GmbH Method of operating an inhalation device, inhalation device and inhalation device system for providing inhalation process/breath guiding
WO2025024609A1 (en) * 2023-07-25 2025-01-30 Biosuperior Technology, Inc. Polypeptides for lung surfactant compositions
WO2025245275A1 (en) * 2024-05-21 2025-11-27 Molecular Express, Inc. Surfactant preparations for pulmonary delivery, and methods for the preparation and use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5400000A (en) 1999-06-11 2001-01-02 Byk Gulden Lomberg Chemische Fabrik Gmbh Pharmaceutical preparation containing modifications of surfactant protein b (sp-b) and surfactant protein c (sp-c)
ITMI20021058A1 (it) * 2002-05-17 2003-11-17 Chiesi Farma Spa Miscele di lipidi sintetici ottimizzate per la preparazione di un surfattante ricostituito
EP1481665A1 (en) * 2003-05-30 2004-12-01 CHIESI FARMACEUTICI S.p.A. Novel lipid mixtures for synthetic surfactants
AU2006244969B2 (en) * 2005-05-11 2011-05-19 Yamasa Corporation Method of stabilizing pulmonary surfactant protein
US8563683B2 (en) 2006-07-20 2013-10-22 University Of Rochester Synthetic lung surfactant and use thereof
MY148127A (en) 2006-10-13 2013-02-28 Chiesi Farma Spa Reconstituted surfactants having improved properties
EP1997502A1 (en) * 2007-06-01 2008-12-03 CHIESI FARMACEUTICI S.p.A. Reconstituted surfactants having improved properties

Also Published As

Publication number Publication date
CO6470858A2 (es) 2012-06-29
KR20120028892A (ko) 2012-03-23
JO3226B1 (ar) 2018-03-08
CY1118676T1 (el) 2017-07-12
BRPI1010120B1 (pt) 2022-12-06
US8399406B2 (en) 2013-03-19
TW201102083A (en) 2011-01-16
ES2621974T3 (es) 2017-07-05
JP5666569B2 (ja) 2015-02-12
HK1166332A1 (en) 2012-10-26
SI2438086T1 (sl) 2017-05-31
CA2764454C (en) 2018-06-12
GEP20135967B (en) 2013-11-11
SG176305A1 (en) 2012-01-30
DK2438086T3 (en) 2017-04-10
PL2438086T3 (pl) 2017-07-31
AU2010256066A1 (en) 2012-01-12
HUE034053T2 (en) 2018-01-29
IL216718A (en) 2016-08-31
EA201190292A1 (ru) 2012-06-29
MA33374B1 (fr) 2012-06-01
KR101668137B1 (ko) 2016-10-20
CN102459327B (zh) 2015-06-03
AR076973A1 (es) 2011-07-20
LT2438086T (lt) 2017-04-10
WO2010139442A1 (en) 2010-12-09
ME01279B (me) 2013-06-20
EP2438086A1 (en) 2012-04-11
EA021163B1 (ru) 2015-04-30
US20110003733A1 (en) 2011-01-06
BRPI1010120A2 (pt) 2019-03-26
EP2438086B1 (en) 2017-01-11
NZ596848A (en) 2013-06-28
PT2438086T (pt) 2017-04-18
CN102459327A (zh) 2012-05-16
TN2011000558A1 (en) 2013-05-24
HRP20170445T1 (hr) 2017-05-19
MY159464A (en) 2017-01-13
CA2764454A1 (en) 2010-12-09
PE20120541A1 (es) 2012-05-12
TWI457132B (zh) 2014-10-21
MX2011012951A (es) 2011-12-16
IL216718A0 (en) 2012-02-29
UA103526C2 (ru) 2013-10-25
JP2012528810A (ja) 2012-11-15
AU2010256066B2 (en) 2015-11-26

Similar Documents

Publication Publication Date Title
CL2011003003A1 (es) Composicion tensioactiva reconstituida que comprende un polipeptido análogo a la proteína surfactante c nativa, un polipeptido análogo a la proteína surfactante b nativa, un fosfolipido monoinsaturado y un fosfolipido saturado, útil para el tratamiento del síndrome de dificultad respiratoria.
AR093569A1 (es) Tensioactivos pulmonares reconstituidos
GT201400111A (es) Triazolopiridinas sustituidas
AR083162A1 (es) Uso de ingredientes activos para controlar nematodos en cultivos resistentes a nematodos
DOP2015000240A (es) 3- pirimidin- 4- il- oxazolidin- 2- onas como inhibidores de idh mutante
CL2018000232A1 (es) Mezcla de péptidos (divisional solicitud 201601405)
CL2015001984A1 (es) (divisional de la sol. 1567-2013) combinaciones de principios activos que comprenden piridiletilbenzamidas y otros principios activos.
CL2012001298A1 (es) Compuestos derivados del acido carbomoil-metilamino acetico sustituido, inhibidores de nep; composicion farmaceutica; combinacion farmaceutica; y uso para el tratamiento de hipertension arterial, hipertension pulmonar, insuficiencia cardiaca, entre otras.
AR113422A2 (es) Agentes tensioactivos reconstituidos que tienen propiedades mejoradas
MX348064B (es) Imidazopiridazinas sustituidas con amino.
MX2012008717A (es) Composiciones para el cuidado oral.
MX366906B (es) Purificacion de iduronato-2-sulfatasa.
MX380453B (es) Metodo para mejorar el valor nutricional de pienso para animales.
CO2018012258A2 (es) Compuestos de mic-1 y usos de estos
NI201500118A (es) Imidazopiridazinas sustituidas
AR083126A1 (es) Composicion vacunal para el control de las infestaciones por ectoparasitos
DOP2017000146A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
CL2013002129A1 (es) Compuestos derivados de acido 3-heteroaroilamino-propionico sustituidos, como inhibidores de la proteasa catepsina a; procedimiento de preparacion; composicion farmaceutica que los comprende; y su uso para el tratamiento de insuficiencia cardiaca, enfermedades inmunologicas, asma, dolor, entre otras.
CR20160235A (es) Tienopirimidinas como inhibidores mknk1 y mknk2
PE20150908A1 (es) Fortificador de la formula
CO2017012675A2 (es) Péptidos lipidados resistentes a proteasas
NI201900063A (es) Amidas aromáticas de ácido carboxílico
MX386107B (es) Composiciones para el cuidado bucal.
AR086207A1 (es) Composiciones y metodos
CL2009001006A1 (es) Compuestos derivados del acido 4-dimetil-aminobutirico; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de enfermedades tales como hiperglucemia, diabetes e hipertension entre otras.